SLS-009, an allele-specific gene therapy, reduces mHTT aggregates in Huntington’s disease mice
June 6, 2023
Researchers from Seelos Therapeutics Inc. presented the discovery and preclinical evaluation of a gene therapy candidate, SLS-009, for the treatment of Huntington’s disease (HD).
